Voyager Therapeutics (VYGR) Cash from Operations Growth (3y) (2017 - 2026)
Powered by 
Analysis
Voyager Therapeutics (VYGR) Cash from Operations Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 61.18% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 13.50% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 40.17% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 53.44% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 16.67% |
| 10 | Voyager Therapeutics | 215.07 Mn | 98.73 Mn | - | -213.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -213.96% |
| Mar 31, 2026 | -31.43% |
| Dec 31, 2025 | -35.21% |
| Sep 30, 2025 | -24.20% |
| Jun 30, 2025 | -21.63% |
| Mar 31, 2025 | -45.82% |
| Dec 31, 2024 | -48.85% |
| Sep 30, 2024 | -10.54% |
| Jun 30, 2024 | -11.61% |
| Mar 31, 2024 | 68.21% |
| Dec 31, 2023 | -2.63% |
| Sep 30, 2023 | 5.24% |
| Jun 30, 2023 | 65.98% |
| Mar 31, 2023 | 84.60% |
| Dec 31, 2022 | 19.37% |
| Sep 30, 2022 | 9.10% |
| Jun 30, 2022 | 16.33% |
| Mar 31, 2022 | -34.97% |
| Dec 31, 2021 | 34.99% |
| Sep 30, 2021 | -5.48% |